Accreditation of the activity of molecular pathology according to ISO 15189: Key steps to follow and the main potential pitfalls;Accréditation de l'activité de pathologie moléculaire selon la norme ISO 15189. Principales étapes à respecter et principaux écueils possibles

Annales de Pathologie

Volumn 33, Issue 1, 2013, Pages 12-23

  Long, élodie ^a   Hofman, Véronique ^a   Ilie, Marius ^a   Washetine, Kevin ^a   Lespinet, Virgine ^a   Bonnetaud, Christelle ^a   Bordone, Olivier ^a   Gavric Tanga, Virginie ^a   Gaziello, Marie Clotilde ^a   Lassalle, Sandra ^a   Selva, éric ^a   Zahaf, Katia ^a   Lamy, Aude ^b   Sabourin, Jean Christophe ^b   Hofman, Paul ^a  

^a PASTEUR HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Accreditation; ISO 15189; Molecular biology; Molecular pathology; Quality assurance

Indexed keywords

ACCREDITATION; ARTICLE; HUMAN; MEDICAL SOCIETY; MOLECULAR PATHOLOGY; PATHOLOGIST; PERSONALIZED MEDICINE; QUALITY CONTROL;

ACCREDITATION; FRANCE; GUIDELINES AS TOPIC; HUMANS; PATHOLOGY, MOLECULAR;

EID: 84875278942     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2012.11.004     Document Type: Article

References (42)

1. Jones D., Fletcher C.D. How shall we apply the new biology to diagnostics in surgical pathology?. J Pathol 1999, 187:147-154.
2. Cheng L., Alexander R.E., Maclennan G.T., Cummings O.W., Montironi R., Lopez-Beltran A., et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012, 25:347-369.
3. De Mattos-Arruda L., Dienstmann R., Tabernero J. Development of molecular biomarkers in individualized treatment of colorectal cancer. Clin Colorectal Cancer 2011, 10:279-289.
4. Dacic S. Molecular diagnostics of lung carcinomas. Arch Pathol Lab Med 2011, 135:622-629.
5. Diaz-Cano S.J. General morphological and biological features of neoplasms: integration of molecular findings. Histopathology 2008, 53:1-19.
6. Eberhard D.A., Giaccone G., Johnson B. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008, 26:983-994.
7. Li J., Chen F., Cona M.M., Feng Y., Himmelreich U., Oyen R., et al. A review on various targeted anticancer therapies. Target Oncol 2012, 7:69-85.
8. La Thangue N.B., Kerr D.J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011, 8:587-596.
9. Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, et al. A review on various targeted anticancer therapies. Target Oncol 2012.
10. Mok T.S. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011, 8:661-668.
11. Woodman S.E., Lazar A.J., Aldape K.D., Davies M.A. New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res 2012, 18:1195-1200.
12. Dietel M., Sers C. Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 2006, 448:744-755.
13. van Krieken J.H., Hoefler G. The times have changed: molecular pathology is here to stay: a commentary on: Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma, by Lee et al. In this issue. Virchows Arch 2012, 460:129-130.
14. Cofrac. Guide technique d'accréditation en biologie médicale. Document SH GTA 01. Révision 00. Mai 2011.
15. Libeer J.C. Effect of accreditation schemes on the setting of quality specifications by laboratories. Scand J Clin Lab Invest 1999, 59:575-578.
16. Medical Laboratories. Particular requirements for quality and competence. International Standard ISO 15189:2007, 2007.
17. Norme NF ISO 15189. Laboratoires d'analyses de biologie médicale. Exigences particulières concernant la qualité et la compétence. AFNOR; 2007.
18. Guide de bonne exécution des analyses (GBEA). Arrêté du 26 novembre 1999 relatif à la bonne exécution des analyses de biologie médicale. JO du 11 décembre 1999 modifié par arrêté du 28 avril 2002 (JO du 4 mai 2002).
19. Wood W.G. The preanalytical phase-can the requirements of the DIN-EN-ISO 15189 be met practically for all laboratories? A view of the " German situation" . Clin Lab 2005, 51:665-671.
20. Journal officiel. Arrêté du 16 juillet 2007 fixant les mesures techniques de prévention, notamment de confinement, à mettre en œuvre dans les laboratoires de recherche, d'enseignement, d'analyses, d'anatomie et cytologie pathologiques, les salles d'autopsie et les établissements industriels et agricoles ou les travailleurs sont suceptibles d'être exposés à des agents biologiques pathogènes. JO du 4 août 2007.
21. Organisation mondiale de la santé. Manuel de sécurité biologique en laboratoire. 3e éd. 2005.
22. Hofman V., Ilie M., Gavric-Tanga V., Lespinet V., Mari M., Lassalle S., et al. Rôle du laboratoire d'anatomie-pathologique dans l'approche pré-analytique des examens de biologie moléculaire réalisés en pathologie tumorale. Ann Pathol 2010, 30:85-93.
23. Bellon E., Ligtenberg M.J., Tejpar S., Cox K., de Hertogh G., de Stricker K., et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011, 16:467-478.
24. Jiang Y., Wang M. Personalized medicine in oncology: tailoring the right drug to the right patient. Biomark Med 2010, 4:523-533.
25. Brambilla E., Lantuejoul S. New classification of pulmonary cancer: application to small size biopsy sampling. Ann Pathol 2010, 30:60-63.
26. Kulesza P., Ramchandran K., Patel J.D. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol 2011, 136:228-238.
27. Leary A.F., Castro D.G., Nicholson A.G., Ashley S., Wotherspoon A., O'Brien M.E., et al. Establishing an EGFR mutation screening service for non-small cell lung cancer - Sample quality criteria and candidate histological predictors. Eur J Cancer 2012, 48:61-67.
28. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
29. Bonin S., Petrera F., Rosai J., Stanta G. DNA and RNA obtained from Bouin's fixed tissues. J Clin Pathol 2005, 58:313-316.
30. Lassalle S., Hofman V., Ilie M., Gavric-Tanga V., Brest P., Havet K., et al. Assessment of morphology, antigenicity, and nucleic acid integrity for diagnostic thyroid pathology using formalin substitute fixatives. Thyroid 2009, 19:1239-1248.
31. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002, 161:1961-1971.
32. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15:3023-3028.
33. Ilie M.I., Hofman V., Bonnetaud C., Havet K., Lespinet-Fabre V., Coelle C., et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010, 457:483-495.
34. Simonetti S., Molina M.A., Queralt C., de Aguirre I., Mayo C., Bertran-Alamillo J., et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 2010, 8:135.
35. Hofman P., Ilie M., Hofman V., Roux S., Valent A., Bernheim A., et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012, 23:1738-1743.
36. Cairns J. The interface between molecular biology and cancer research. Mutat Res 2000, 462:423-428.
37. Rauch C.A., Nichols J.H. Laboratory accreditation and inspection. Clin Lab Med 2007, 27:845-858.
38. Raymaekers M., Bakkus M., Boone E., de Rijke B., El Housni H., Descheemaeker P., et al. MolecularDiagnostics.be working group. Reflections and proposals to assure quality in molecular diagnostics. Acta Clin Belg 2011, 66:33-41.
39. Cronin M., Ross J.S. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 2011, 5:293-305.
40. Ladanyi M., Hogendoorn P.C. Cancer biology and genomics: translating discoveries, transforming pathology. J Pathol 2011, 223:99-101.
41. Pao W., Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007, 13:4954-4955.
42. Yauch R.L., Settleman J. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Curr Opin Genet Dev 2012, 22:45-49.